Cyclopharm (ASX:CYC) has announced that the United States Patent and Trademark Office (USPTO) has granted the maximum allowable patent term extension of five years covering the TECHNEGAS Kit (technetium Tc-99m labelled carbon) to 2031.
The company said this milestone follows a comprehensive review by both the USPTO and the US FDA, which confirmed that the patent covering TECHNEGAS qualified for a term extension. As a result, the original patent, previously set to expire in 2026, has now been extended to 2031. The five-year extension granted represents the maximum duration permitted under US law.
Cyclopharm said the patent extension provides a significant competitive advantage and ensures a clear runway for value creation in the world’s largest healthcare market. It allows Cyclopharm to realise the full commercial and clinical potential of TECHNEGAS in the US in both diagnosing pulmonary embolism and a growing number of indications without the risk of near-term generic or biosimilar competition.
Cyclopharm Managing Director, James McBrayer, said, “The granting of the maximum allowable U.S. patent term extension is a significant achievement for TECHNEGAS. This outcome reflects several years of diligent and strategic work that has been progressing in the background while we worked toward U.S. FDA regulatory approval. It validates our long-term commitment to protecting the value of our technology and provides a strong foundation as we accelerate our U.S. commercialisation efforts with additional business development personnel.